A
Antares Pharma Inc
NASDAQ:ATRS
Antares Pharma Inc
NASDAQ:ATRS
Price:
5.59 USD
Market Closed
Updated:
May 5, 2024
Antares Pharma Inc
Revenue
|
Antares Pharma Inc
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Antares Pharma Inc
NASDAQ:ATRS
|
Revenue
$184m
|
CAGR 3-Years
43%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
Antares Pharma Inc
Revenue Breakdown
Breakdown by Geography
Antares Pharma Inc
Antares Pharma Inc
Not Available
Breakdown by Segments
Antares Pharma Inc
Antares Pharma Inc
|
Total Revenue:
184m
USD
|
|
Product:
126.7m
USD
|
|
Royalty:
37.7m
USD
|
|
Licensing And Development Revenue:
19.6m
USD
|
See Also
What is Antares Pharma Inc's Revenue?
Revenue
184m
USD
184m
USD
Based on the financial report for Dec 31, 2021, Antares Pharma Inc's Revenue amounts to 184m USD.
What is Antares Pharma Inc's Revenue growth rate?
Revenue CAGR 5Y
29%
29%
Over the last year, the Revenue growth was 23%. The average annual Revenue growth rates for Antares Pharma Inc have been 43% over the past three years , 29% over the past five years .
You don't have any saved screeners yet
